Munich

• DOUBLE PRO-TECT Alport: A confirmatory, multicenter, randomized, double-blind, placebo-controlled clinical trial to assess the effect of Dap … Recruiting
  2023-508502-18-00 5 2024-03-19 Alport syndrome
• ​​Lomustine with or without a second round of brain radiation for the reappearance of glioblastoma Recruiting
  2023-505267-36-00 5 2024-03-15 Glioblastoma
• Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schizophrenia by Targeting Myelin Plasticity (OligoTreat) Recruiting
  2024-514457-30-00 4 2024-02-26 Schizophrenia
• An international, multicenter, randomised, superiority phase III, open label, 2-arm study to investigate distant metastasis free survival wi … Recruiting
  2022-501453-36-00 5 2024-02-23 Breast cancer
• Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib … Recruiting
  2023-503708-10-00 5 2024-02-20 Locally advanced or metastatic breast cancer
• An Open-label Study of XEN1101 in Epilepsy Recruiting
  2022-502282-24-00 5 2024-02-14 Primary generalized tonic-clonic seizures
• Prospective, placebo-controlled clinical trial with Aconite Pain Oil in oncological patients under-going chemotherapy to prevent chemotherap … Recruiting
  2022-502889-24-00 5 2024-02-13 chemotherapy-induced polyneuropathy (CIPN)
• A study in men with advanced prostate cancer to determine the safety and effects of a test drug (Lutetium (177Lu) rhPSMA 10.1 injection) Recruiting
  2024-511537-35-00 9 2024-02-09 Metastatic castration-resistant prostate cancer (mCRPC)
• Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults with Active Sjögren’s Syndrome Recruiting
  2023-503327-26-00 5 2024-01-31 Sjogren's syndrome
• Clinical and translational controlled study of Perampanel treatment around Surgery in patients with progressive glioblastoma (PerSurge) Recruiting
  2023-503938-52-00 4 2024-01-26 Progressive Glioblastoma
• A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N … Recruiting
  2022-502980-39-00 5 2024-01-25 Estrogen receptor (ER)-positive, HER2-negative advanced breast cancer
• A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY OF CLN-049 FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) PATIENTS WITH M … Recruiting
  2023-506572-27-00 3 2024-01-12 Acute Myeloid Leukemia (AML) with Measurable Residual Disease (MRD)
• Effect of acyclovir therapy on the outcome of ventilated patients with lower respiratory tract infection and detection of herpes simplex vir … Recruiting
  2023-504322-19-00 5 2024-01-10 Patients in the intensive care unit on ventilation with pneumonia and
• A trial to learn if odronextamab combined with lenalidomide is safe and works better than rituximab combined with lenalidomide in adult part … Recruiting
  2022-503092-28-00 5 2024-01-08 Relapsed/Refractory Follicular Lymphoma
• A study to test how effective belumosudil tablets are for treating adult participants with chronic lung allograft dysfunction Recruiting
  2023-503462-23-00 5 2023-12-28 Lung transplant rejection
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for SC use) versus plac … Recruiting
  2022-502046-28-00 5 2023-12-22 HER2-Positive, PIK3CA Mutated, Locally Advanced or Metastatic Breast C
• Study on the effect of 2 immunotherapy drugs in combination with radioactive glass spheres on the survival in liver cancer Recruiting
  2024-515127-11-00 4 2023-12-21 hepatocellular carcinoma
• A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic B … Recruiting
  2022-503114-23-00 3 2023-12-19 Breast Cancer
• A study to investigate the safety and clinical activity of belantamab for the treatment of multiple myeloma when used as monotherapy and in … Recruiting
  2022-501941-63-00 7 2023-12-13 Multiple myeloma
• Safety and immunologic response of SHIngrix VAccination in patients suffering from Psoriasis or Psoriatic arthritis Recruiting
  2024-512881-32-00 6 2023-11-22 Psoriasis vulgaris and/or psoriatric arthritis
• Long-term neuropsychologic outcome of pre-emptive mTOR inhibitor treatment in children with tuberous sclerosis complex (TSC) under 4 months … Recruiting
  2022-502332-39-00 4 2023-11-15 Tuberous sclerosis complex (TSC)
• A study to examine the safety, tolerablity, body distribution and efficacy of [90Y]Y-PentixaTher therapy in CNS lymphoma patients. Recruiting
  2024-512097-98-00 9 2023-11-07 Central nervous system (CNS) lymphoma; recurrent or refractory primary
• Expression-linked and R-ISS-adapted stratification for first line therapy in multiple myeloma patients (ELIAS) Recruiting
  2022-500453-16-00 4 2023-10-30 Multiple Myeloma
• Staphylococcus aureus Network Adaptive Platform trial (SNAP) Recruiting
  2023-503582-35-00 6 2023-10-26 Staphylococcus aureus bacteremia

Showing 433–456 of 1,080 trials